EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Aplastic anemia associated with parvovirus B19 infection following neoadjuvant pembrolizumab-based chemoimmunotherapy for triple-negative breast cancer

Jan Kindl, Dominika Svobodová, Martin Matějů, Martina Zimovjanová, Michal Vočka, Petra Kovaříková, Zuzana Bielčiková

Frontiers in Oncology · 10.07.2026 · 16

DOI: 10.3389/fonc.2026.1834150 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 10.07.2026. Verfasst von Jan Kindl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague, Prague, Czechia. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Univerzita Karlova v Praze.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors are increasingly incorporated into curative treatment strategies for early-stage triple-negative breast cancer. Although hematologic immune-related adverse events are rare, they may be severe and difficult to distinguish from other causes of bone marrow failure. We report a 54-year-old woman with triple-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy according to the KEYNOTE-522 regimen. After breast-conserving surgery and achievement of a pathologic complete response, she developed a rapidly progressive severe pancytopenia (grade 4 febrile neutropenia, grade 4 thrombocytopenia and grade 3 anemia) in the early postoperative period. Bone marrow biopsy showed generalized bone marrow suppression. An immune-related hematologic toxicity was suspected; high-dose corticosteroids were initiated. However, no hematologic response was observed. Further tests detected ongoing parvovirus B19 infection (positive plasma viral DNA and IgM and IgG serology). Intravenous immunoglobulin therapy was therefore initiated, resulting in rapid hematologic recovery. Pembrolizumab was discontinued, and the patient subsequently completed adjuvant radiotherapy. At a 20-month follow-up, she remained free of disease recurrence. This case highlights the importance of broad diagnostic evaluation of severe cytopenias after pembrolizumab-based chemoimmunotherapy and underscores the need to distinguish infectious bone marrow suppression from primary immune-related hematologic toxicity, as this distinction may directly influence management.

Schlagwörter

Stichwörter der Autor:innen

aplastic anemiaimmune checkpoint inhibitorsimmune-related adverse eventsintravenous immunoglobulinspancytopeniaparvovirus B19pembrolizumabtriple-negative breast cancer

Autor:innen und Institutionen

  • Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague, Prague, Czechia.
  • Hematology, First Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University Prague, Prague, Czechia.

Förderung

  • Univerzita Karlova v Praze

Zitieren

APA

Kindl, J., Svobodová, D., Matějů, M., Zimovjanová, M., Vočka, M., Kovaříková, P., & Bielčiková, Z. (2026). Case Report: Aplastic anemia associated with parvovirus B19 infection following neoadjuvant pembrolizumab-based chemoimmunotherapy for triple-negative breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1834150

Vancouver

Kindl J, Svobodová D, Matějů M, Zimovjanová M, Vočka M, Kovaříková P, et al. Case Report: Aplastic anemia associated with parvovirus B19 infection following neoadjuvant pembrolizumab-based chemoimmunotherapy for triple-negative breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1834150

BibTeX
@article{Kindl2026,
  author = {Kindl, Jan and Svobodová, Dominika and Matějů, Martin and Zimovjanová, Martina and Vočka, Michal and Kovaříková, Petra and Bielčiková, Zuzana},
  title = {Case Report: Aplastic anemia associated with parvovirus B19 infection following neoadjuvant pembrolizumab-based chemoimmunotherapy for triple-negative breast cancer},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1834150}
}
Kostenlos starten →